Needham analyst Ami Fadia maintains $Revolution Medicines (RVMD.US)$ with a buy rating, and adjusts the target price from $68 to $62.
According to TipRanks data, the analyst has a success rate of 47.3% and a total average return of 4.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
The firm adjusted its valuation model following Revolution Medicines' completion of an upsized public offering totaling $862.5M in common stock. The firm still perceives significant potential in Revolution Medicines' RAS-ON platform, highlighting the prospect of combining two RAS-ON drugs or using them in conjunction with other treatments.
Revolution Medicines initiated a stock offering of roughly 19M common shares and about 2.17M in pre-funded warrants priced at $46 per share, thereby raising total gross proceeds of $862.5M. This strategic financial move came on the heels of new positive clinical data for RMC-6236 in treating non-small cell lung cancer, which demonstrated a promising 38% overall response rate and a median progression-free survival of 9.8 months in third-line RAS-mutant NSCLC patients. Analysts continue to believe that RAS(ON) inhibitors will significantly alter the standard of care across several RAS-mutant solid tumors, including non-small cell lung cancer and pancreatic ductal adenocarcinoma, suggesting that the recent market adjustments present a favorable buying opportunity for investors in Revolution Medicines.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Needham分析师Ami Fadia维持$Revolution Medicines (RVMD.US)$买入评级，并将目标价从68美元下调至62美元。
根据TipRanks数据显示，该分析师近一年总胜率为47.3%，总平均回报率为4.7%。
此外，综合报道，$Revolution Medicines (RVMD.US)$近期主要分析师观点如下：
该公司在小基站-5g完成总额为86250万美元的普通股份公开发行之后调整了其估值模型。该公司仍然认为在revolution medicines的RAS-ON平台中存在重大潜力，强调了结合两种RAS-ON药物或与其他治疗方法联合使用的前景。
revolution medicines发起了一项大约1900万普通股和约217万预资劵的股票发行，发行价为46美元每股，从而筹集了总计86250万美元的总权利净收益。这一战略性财务举措是基于对RMC-6236在治疗非小细胞肺癌方面的新积极临床数据，该数据显示在三线RAS突变NSCLC患者中，RMC-6236表现出令人期待的38%总体反应率和中位无病进展生存时间高达9.8个月。分析师继续认为RAS(ON)抑制剂将显著改变几种RAS突变的固体肿瘤的标准治疗方法，包括非小细胞肺癌和胰腺导管腺癌，暗示最近的市场调整为revolution medicines的投资者提供了有利的买入机会。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
